| Schedule (route) | Endpoint | Vehicle | Dose | Treated/Control (%) | Observations |
|---|---|---|---|---|---|
| Q01DX009 (ip) | median survival time | saline | 0.25 mg/kg/injection | 108.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 0.25 mg/kg/injection | 94.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 0.32 mg/kg/injection | 97.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 0.5 mg/kg/injection | 109.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 0.5 mg/kg/injection | 103.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 0.5 mg/kg/injection | 113.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.63 mg/kg/injection | 99.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 1.0 mg/kg/injection | 119.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 1.0 mg/kg/injection | 130.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 1.0 mg/kg/injection | 119.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 1.25 mg/kg/injection | 100.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 1.33 mg/kg/injection | 125.0 | Antitumor endpoint evaluated on day 45; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 154.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 137.0 | Antitumor endpoint evaluated on day 45; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 157.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 142.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 2.5 mg/kg/injection | 137.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 3.0 mg/kg/injection | 192.0 | Antitumor endpoint evaluated on day 45; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 4.0 mg/kg/injection | 100.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 4.0 mg/kg/injection | 93.0 | Antitumor endpoint evaluated on day 30; 09/10 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 4.0 mg/kg/injection | 120.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 5.0 mg/kg/injection | 90.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 8.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (sc) | median survival time | saline | 0.5 mg/kg/injection | 107.0 | Antitumor endpoint evaluated on day 45; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (sc) | median survival time | saline | 0.5 mg/kg/injection | 104.0 | Antitumor endpoint evaluated on day 30; 07/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (sc) | median survival time | saline | 1.0 mg/kg/injection | 110.0 | Antitumor endpoint evaluated on day 45; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (sc) | median survival time | saline | 1.0 mg/kg/injection | 110.0 | Antitumor endpoint evaluated on day 30; 08/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (sc) | median survival time | saline | 1.33 mg/kg/injection | 130.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (sc) | median survival time | saline | 2.0 mg/kg/injection | 146.0 | Antitumor endpoint evaluated on day 45; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (sc) | median survival time | saline | 2.0 mg/kg/injection | 143.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (sc) | median survival time | saline | 2.0 mg/kg/injection | 128.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (sc) | median survival time | saline | 3.0 mg/kg/injection | 173.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (sc) | median survival time | saline | 4.0 mg/kg/injection | 126.0 | Antitumor endpoint evaluated on day 45; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (sc) | median survival time | saline | 4.0 mg/kg/injection | 143.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (sc) | median survival time | saline | 4.0 mg/kg/injection | 149.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (sc) | median survival time | saline | 8.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 45; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (sc) | median survival time | saline | 8.0 mg/kg/injection | 113.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (sc) | median survival time | saline | 8.0 mg/kg/injection | 117.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (sc) | median survival time | saline | 16.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 00/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (sc) | median survival time | saline | 32.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 00/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX002 (oral) | median survival time | saline | 20.0 mg/kg/injection | 131.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q04DX002 (oral) | median survival time | saline | 30.0 mg/kg/injection | 122.0 | Antitumor endpoint evaluated on day 30; 09/09 animals surviving on day 5 |
| Q04DX002 (oral) | median survival time | saline | 40.0 mg/kg/injection | 131.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q04DX002 (oral) | median survival time | saline | 50.0 mg/kg/injection | 130.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |